Jun 10, 2020
Johnson & Johnson Announces Acceleration of its COVID-19 Vaccine Candidate; Phase 1/2a Clinical Trial to Begin in Second Half of July
Jun 01, 2020
AcelRx Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
May 04, 2020
AcelRx to Host First Quarter 2020 Financial Results Call and Webcast on Monday, May 11th, 2020
Apr 28, 2020
Philogen Announces Option Exercise by Janssen
Apr 23, 2020
Johnson & Johnson Announces Collaboration to Expand Manufacturing Capabilities For its COVID-19 Vaccine Candidate in Support of the Company's Goal to Supply More Than One Billion Vaccine Doses Globally
Mar 30, 2020
Johnson & Johnson Announces a Lead Vaccine Candidate for COVID-19; Landmark New Partnership with U.S. Department of Health & Human Services; and Commitment to Supply One Billion Vaccines Worldwide for Emergency Pandemic Use
Mar 17, 2020
Vivante Health Announces Collaboration with Janssen for Predictive Disease Modeling
Mar 02, 2020
European Medicines Agency Grants PRIME and Advanced Therapy Medicinal Product Designations to Janssen's RPGR Gene Therapy for X-Linked Retinitis Pigmentosa
Jan 13, 2020
Upsher-Smith Launches Haloperidol Tablets, USP
Jan 13, 2020
AcelRx Announces Year-End 2019 Metrics and Provides Corporate Updates
Jan 07, 2020
Protagonist Therapeutics Achieves Milestone in Janssen Biotech, Inc., Collaboration
Dec 30, 2019
Janssen Announces Completion of Acquisition of Investigational Bermekimab from XBiotech Inc.
Dec 21, 2019
Complete Response Letter Issued from U.S. FDA for Investigational Long-Acting HIV Regimen
Dec 07, 2019
Janssen to Acquire Investigational Bermekimab from XBiotech
Nov 25, 2019
INHIBITOR Therapeutics Submits Investigational New Drug Application for Treatment of Patients with Late-Stage Prostate Cancer
Nov 05, 2019
AcelRx Pharmaceuticals to Present at Credit Suisse 28th Annual Healthcare Conference
Oct 02, 2019
Janssen Submits Supplemental New Drug Application to U.S. FDA for SPRAVATO® (esketamine) CIII Nasal Spray for the Rapid Reduction of Depressive Symptoms in Adults with Major Depressive Disorder Who Have Active Suicidal Ideation with Intent
Oct 01, 2019
Johnson & Johnson Reaches Settlement Agreement with Two Ohio Counties Ahead of Upcoming Opioid Trial
Sep 03, 2019
Janssen Announces U.S. FDA Breakthrough Therapy Designation for Investigational Prophylactic Vaccine for the Prevention of Respiratory Syncytial Virus in Older Adults
Aug 26, 2019
Johnson & Johnson To Appeal Flawed Opioid Judgment in Oklahoma